Leukemia, Myelogenous, Chronic Clinical Trial
Official title:
A Bioequivalence Study Between the Generic Dasatinib Tablet and Reference Product in Vivo
This is a clinical study to evaluate the bioequivalence of dasatinib tablet produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Sprycel® produced by Bristol Myers Squibb after single dose in healthy subjects, so as to provide reference for clinical evaluation and clinical medication; to observe the safety of the dasatinib tablet and the reference drug Sprycel® in healthy subjects under fasting and fed states.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03421626 -
Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)
|
||
| Completed |
NCT01720264 -
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
|
Phase 2 | |
| Completed |
NCT00241358 -
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00862719 -
Sitagliptin Umbilical Cord Blood Transplant Study
|
Phase 2 | |
| Recruiting |
NCT00619879 -
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
|
Phase 3 | |
| Completed |
NCT00129740 -
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
|
Phase 2 | |
| Completed |
NCT02117115 -
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 0 | |
| Terminated |
NCT00569179 -
A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies
|
Phase 1 |